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Abstract
Background: Members of the Peroxisome Proliferator Activated Receptor, PPAR, subfamily of nuclear receptors display
complex opposing and overlapping functions and a wide range of pharmacological and molecular genetic tools have been
used to dissect their specific functions. Non-agonist bound PPARd has been shown to repress PPAR Response Element,
PPRE, signalling and several lines of evidence point to the importance of PPARd repressive actions in both cardiovascular
and cancer biology.
Methodology/Principal Findings: In this report we have employed transient transfections and luciferase reporter gene
technology to study the repressing effects of PPARd and two derivatives thereof. We demonstrate for the first time that the
classical dominant negative deletion of the Activation Function 2, AF2, domain of PPARd show enhanced repression of PPRE
signalling in the presence of a PPARd agonist. We propose that the mechanism for the phenomenon is increased RXR
heterodimerisation and DNA binding upon ligand binding concomitant with transcriptional co-repressor binding. We also
demonstrated ligand-dependent dominant negative action of a DNA non-binding derivative of PPARd on PPARc1 signalling.
This activity was abolished upon over-expression of RXRa suggesting a role for PPAR/cofactor competition in the absence of
DNA binding.
Conclusions/Significance: These findings are important in understanding the wide spectrum of molecular interactions in
which PPARd and PPARc have opposing biological roles and suggest novel paradigms for the design of different functional
classes of nuclear receptor antagonist drugs.
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Introduction
The peroxisome proliferator-activated receptors (PPARs) a, d
and c belong to the nuclear receptor family of transcriptional
regulators. They function as obligate heterodimers with the
retinoid X receptors, RXRs, and signal from PPAR response
elements (PPREs) upon binding PPAR- and/or RXR agonists.
The PPAR ligands consist of naturally occurring fatty acids and
fatty acid derivatives as well as a range of synthetic drugs [1,2,3].
PPARa is involved in the control of catabolic fatty acid
metabolism such as peroxisomal b-oxidation and mitochondrial b-
and v-oxidation of fatty acids and is most prevalent in
metabolically active tissues such as liver. PPARa is activated by
the blood lipid lowering fibrate drugs. These acts as peroxisome
proliferators in mice and rats but no adverse effects have been
detected in human livers [1,4].
PPARc is involved in fatty acid and glucose homeostasis and is
required for adipocyte differentiation and for placental develop-
ment. Activation of PPARc also seems to act anti-inflammatory
and to hinder proliferation or cause apoptosis in cancer cells. The
insulin sensitizing thiazolidinedione drugs, which are high affinity
PPARc agonists, are used to treat type 2 diabetes and
experimentally to treat cancer [5].
PPARd is widely expressed and the most prevalent PPAR in
several tissues both in the adult organism and during development
[6]. It is also the least known in terms of biological function,
although recent reports would suggest that it might have a role
similar to PPARa in tissues other than liver. PPARd has also been
shown to be involved in placental implantation, wound healing,
and carcinogenesis [4,7,8,9]. No PPARd ligands are currently used
as such in treatment of disease, although studies on human
subjects for the use of a PPARd agonist in the treatment of
metabolic syndrome have been reported [10,11].
Recently, it was shown that non-liganded PPARd attracts
transcriptional co-repressors when bound to DNA more effectively
than PPARa and c. Due to its widespread distribution it was
suggested that PPARd acts as a PPRE gateway receptor [12,13].
Given the, sometimes conflicting, results on PPARd biology
obtained using various pharmacological and molecular genetic
tools we set out to study the ligand modulated antagonism of
PPARc1 by genomic and non-genomic actions of PPARd.W e
found in accordance with [13] that non-liganded PPARd represses
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7046PPARa and c. In line with this the PPARd derivative
PPARdDAF2, lacking helix 12 (or activation function 2, AF2),
acts dominant negatively on PPARa, c1 and d signalling.
Furthermore, we found that PPARdDAF2 possess ligand
enhanced dominant negative activity on PPRE signalling. In
contrast to Shi et al. [13] who reported that a non-DNA binding
PPARd derivative didn’t exert any dominant negative effects, we
found that non-DNA bound PPARd ligand-binding domain (LBD)
exerts ligand-dependent dominant negative activity on PPARc1
signalling. Since PPARd and c co-exist in a range of tissues and in
many cases have opposite biological effects we propose that the
phenomena discovered might have important implications for
PPAR experimental designs, PPAR biology in general and possibly
drug design.
Results and Discussion
Agonist non-bound PPARd is a repressor of PPARc1
dependent PPRE signalling, but not vice versa
Due to its widespread tissue distribution and the fact that it
interacts more efficiently on DNA with nuclear receptor co-
repressors than the other PPAR isoforms it was proposed, as well
as demonstrated in vitro, that PPARd functions as a PPRE gateway
receptor [12,13]. We confirmed this phenomenon for PPARd and
c1 signalling using transient transfection of COS-1 cells with
plasmids encoding these PPAR isoforms and a promiscuous
(transcriptionally transactivated by all three PPAR isoforms, data
not shown for PPARa), PPRE luciferase reporter gene construct
(pLFABPluc). We found that the presence of unliganded PPARc1
did not affect PPARd signalling (Figure 1A) whereas unliganded
PPARd significantly (P,0.001) repressed the PPARc1 dependent
signalling from pLFABPluc (Figure 1B).
Ligand-enhanced dominant negative action of
PPARdDAF2
Helix 12 modifications (both designed and for PPARc, found in
human patients as mutations) have been shown to render PPARs
dominant negative due to their inability to recruit co-activators
while retaining the ability to bind co-repressors [14,15,16]. Given
the superior repressing properties of PPARd, modification of helix
12 should render it a relatively effective ligand independent
repressor of PPRE signalling. We have previously employed a
PPARd derivative lacking the C-terminal 11 amino acid residues,
PPARdDAF2, as a tool for studying PPRE signalling [17]. In order
to further characterize the properties of this construct we
conducted a range of transient transfection experiments. PPARd-
DAF2 was found to act in a dominant negative fashion on PPARa,
c1 and d signalling (Figure 2A & B, respectively, P,0.001, data
not shown for PPARa), thus confirming and extending our
previous observations.
Upon agonist binding PPARs undergo a conformational change
leading to increased RXR heterodimerisation and shedding of
transcriptional co-repressors with the subsequent recruitment of
transcriptional co-activators [3]. The increased PPAR-RXR
heterodimerisation leads to an increased affinity for PPREs
[18,19]. This would in the case of PPARdDAF2 lead to increased
occupancy of the PPREs concomitant with recruitment of
transcriptional co-repressors and thus further reduced PPRE
signalling. We thus investigated the effect of a PPARd agonist on
the dominant negative properties of PPARdDAF2. Because of the
relatively high endogenous PPRE signalling in the COS-1 cells we
employed T47D cells grown in RPMI 1640 medium supplement-
ed with 5% dextran charcoal-stripped serum for this experiment.
The effect of over-expressing and transactivating PPARd in T47D
cells is shown in Figure 2D. We could detect a small but significant
(P,0.001) PPARd (CF dependent) activity in cells with no added
PPARd expression vector (Figure 2C). We could also see a small
but significant (P,0.01) effect of introducing PPARdDAF2 on
non-CF dependent transcription of the luciferase gene in
pLFABPluc (Figure 2C). The dominant negative effect of
introducing PPARdDAF2 into the system was further enhanced
by the addition of CF (P,0.001). This indicates that for
PPARdDAF2 CF acts as an inverse agonist that enhances the
dominant negative effect, a novel concept for type II nuclear
receptors. The concept was discussed and investigated for the only
PPARd antagonist described to date, GSK0660. GSK0660 did
Figure 1. The effect of (A) non-liganded PPARc1 on PPARd signalling and of (B) non-liganded PPARd on PPARc1 signalling. COS-1
cells were transiently transfected with (per well in six-well plates) 50 ng (A) pCLDN-hPPARd or (B) pCDLN-hPPARc1 and 250 ng (A) pCLDN or pCLDN-
hPPARc1 and (B) pCLDN or pCLDN-hPPARd, respectively.
doi:10.1371/journal.pone.0007046.g001
PPARd Mediated Repression
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repressors to chromatin PPREs [20].
The PPARd ligand-binding domain is a repressor of PPRE
dependent PPARc1 signalling in the presence of a PPARd
agonist
Since the PPARs act as RXR heterodimers it would be
conceivable that RXR competition could occur among the PPAR
isoforms. In fact, ligand dependent RXR competition has been
described for PPARa and liver X receptor (LXR) [21,22],
PPARb/d and LXRa [23], PPARa and thyroid hormone receptor
(TR) [24] as well as PPARc and TRa1 and b mutants [25,26].
Agonist-bound wild-type PPARd and c activate transcription
when bound to PPREs. Thus, in order to study the PPRE
independent effects of PPARd and c we needed a non-DNA
binding derivative with a functional ligand binding and activating
domain. We generated an expression plasmid for the PPARd
LBD, pCLDN-dLBD, and tested it for the desired properties in a
mammalian two-hybrid assay. Co-expression of the GAL4-RXRa
fusion protein and the PPARd LBD led to CF induced upstream
activating sequence (UAS) dependent transcriptional transactiva-
tion, strongly indicating that the PPARd LBD is functional with
respect to RXR heterodimerisation and transcriptional co-
activator recruitment (Figure 3A, P,0.001).
Subsequent to the functional validation of the PPARd LBD we
investigated whether it had a dominant negative effect on PPARd
and c1 signalling. We found that PPARd but not PPARc1
signalling was abolished by co-expression of the PPARd LBD
(Figures 3B (P,0.001) and C, respectively). One important
Figure 2. PPARdDAF2 represses (A) PPARd and (B) PPARc1 signalling. (C) PPARdDAF2 represses TK-promoter activity in a ligand-
enhanced fashion. COS-1 cells were transiently transfected with (per well in six-well plates) (A) 50 ng pCLDN-hPPARd or (B) pCDLN-hPPARc1 and
250 ng pCLDN or pCLDN-hPPARdDAF2. (C) and (D) T47D cells were transfected with (per well in a six-well plate) 500 ng pCLDN, pCLDN-hPPARdDAF2
or pCLDN-hPPARd. (D) is identical to (C) except for the two additional bars representing over-expression of PPARd with and without CF.
doi:10.1371/journal.pone.0007046.g002
PPARd Mediated Repression
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absence of the CF in 3C. If a PPARd agonist is required for
efficient RXR heterodimerisation then the addition of CF would
render the PPARd LBD dominant negative on PPARc1 signalling.
Indeed, we found that the PPARd LBD could repress the PPARc1
signalling in the presence of a PPARd agonist (Figures 3D,
P,0.001).
Given the known effects of agonist binding to a PPAR one could
speculate whether the dominant negative effect of the PPARd
LBD is due to RXR or transcriptional co-activator squelching. To
address this question we co-expressed RXRa and the transcrip-
tional co-activator, steroid receptor co-activator 1a (SRC1a), with
PPARd and c1 with and without the PPARd LBD. PPARd
signalling was found to be repressed by co-expression of the
PPARd LBD (Figure 4A and B, P,0.001 and P,0.05,
respectively). This dominant negative effect was abolished by co-
expression of RXRa (Figure 4A, P.0.05). Co-expression of
SRC1a with PPARd increased the agonist dependent inducibility
of reporter activity but didn’t abolish the effects of PPARd LBD
dependent repression (Figure 4B).
We then proceeded to study the effect of RXRa and SRC1a co-
expression on the effect of the PPARd LBD on PPARc1 signalling.
In this experimental setup the PPARd LBD showed dominant
negative behaviour in the absence of CF (Figures 4C and D,
P,0.001 and P,0.05, respectively). The dominant negative effect
of the PPARd LBD was somewhat enhanced by the PPARd
agonist (Figures 4C and D). The effect of co-expression of RXRa
was similar to that of the PPARd experiment with overall activity
somewhat increased but with lower levels of PPARc agonist
dependent induction and in abolishing the dominant negative
effect of the PPARd LBD (Figure 4C). Co-expression of SRC1a
increased the level of activity of PPARc1 without having a much of
Figure 3. (A) The PPARd LBD is functional with respect to transcriptional transactivation and RXR heterodimerisation and (B), (C) and
(D) possess ligand-dependent dominant negative behaviour. (A) COS-1 cells were transfected with 500 ng pCMVgRXR and 500 ng pCLDN or
pCLDN-dLBD. (B), (C)and (D)COS-1 cells were transiently transfected with: (B)500 ng pJ3Nuc (hPPARd expression plasmid) and0 to 500 ng pCLDN or
pCLDN-dLBD; (C) 50 ng pCLDN-hPPARc1 and 0 to 500 ng pCLDN or pCLDN-dLBD; (D) 50 ng pCLDN-hPPARc1 and 500 ng pCLDN-dLBD.
doi:10.1371/journal.pone.0007046.g003
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repressed PPARc1 signalling (P,0.05) with additional repression
seen in the presence of CF (Figure 4D). As was the case for
PPARd, the addition of SRC1a increased the overall levels of
signalling (Figure 4D). Also similarly with the SRC1a co-
expression experiment with PPARd the addition of SRC1a did
not abolish the PPARd LBD mediated repression. Instead, the
level of PPARd LBD mediated repression became more
pronounced (Figure 4D, P,0.001). Furthermore, the PPARd
agonist enhanced repression was more marked (Figure 4D,
P,0.05). Since the addition of RXRa seems to relieve the PPARd
LBD mediated repression of PPARd and PPARc1 signalling
whereas the addition of SRC1a still allows the PPARd LBD
mediated repression we conclude that RXR sequestration is likely
to be the main mechanism behind the phenomenon. We thus
speculate that ligand dependent RXR competition could occur in
vivo between at least PPARd and PPARc and quite possible
between all three PPAR isoforms.
Concluding remarks
The major conclusion we draw from this study is that care must
be taken when interpreting results obtained from all genetic
models of PPARd action. The genetic ablation of PPARd will
remove both the ability to activate PPARd, but also the intrinsic
role that PPARd has in the tempering of PPARa and PPARc
signalling. Therefore it is prudent to use a wide range of both gain
and loss of function experiments in order to fully understand the
function of PPARd and its relationship to PPARa and PPARc
Figure 4. The effect of co-expression of RXRa and SRC1a on PPARd LBD mediated repression of PPARd (A and B) and PPARc1 (C and
D) signalling, respectively. COS-1 cells were transfected with: (A and B) 500 ng pJ3Nuc and the following plasmids: 500 ng pCLDN or pCLDN-
dLBD and pCLDN or (A) pSG-mRXRa or (B) pSG5-SRC1a and for (C and D) 50 ng pCLDN-hPPARc1 and the following plasmids: 500 ng pCLDN or
pCLDN-dLBD and 500 ng pCLDN or (C) pSG-mRXRa or (D) pSG5-SRC1a.
doi:10.1371/journal.pone.0007046.g004
PPARd Mediated Repression
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forming heterodimers with RXRs as well.
Our study also might suggest a novel paradigm for the design of
different functional classes of type II nuclear receptor antagonist
drugs. One could envisage two sets of nuclear receptor antagonists
with very different biological actions (simplistically stating the two
extremes of antagonist behaviour); one that displaces the PPAR/
RXRcomplexfromthePPREandonethatsimultaneouslyincreases
DNA binding and transcriptional co-repressor recruitment.
Materials and Methods
Cloning and plasmids
General DNA techniques were performed according to [27].
DNA sequencing was done by the DNA Analysis Facility, Human
Genetics Unit, at Ninewells Hospital, Dundee. Escherichia coli XL1
Blue was transformed according to the manufacturer’s instructions
(Stratagene).
The expression plasmids pCLDN-hPPARd (pMGD60),
pCLDN-hPPARdDAF2, pCLDN-hPPARc1, pJ3NUC, pCMVg-
RXR, pSG-mRXRa and pSG5-SRC1a as well as the PPRE
reporter plasmid pLFABPluc have been described previously
[17,28,29,30,31,32,33]. The internal transfection control plasmid
pSVb-galactosidase is from Promega. The part of human PPARd
encoding the LBD (from codon A142, including an added
translational start codon, in bold) was amplified with primers
PRMG4 (59-CGGGGTACCATGGCTATCCGTTTTGGTCG-
GATG-39) and PRMG5 (59-CGGGGTACCTTAGTACATG-
TCCTTGTAGATCTCC-39)( KpnI-sites underlined). The KpnI
cleaved PCR product was cloned into pCLDN [34], creating
pCLDN-dLBD (confirmed by sequencing). A GAL4-fusion
luciferase reporter plasmid (p46UAS-TK-luc) was constructed
by cloning the SalI-XhoI fragment of pLacZr [30] (containing the
46UAS-TK, Upstream Activating Sequence) module in pGL3ba-
sic (Promega) cleaved with XhoI.
Growth of cells and transient transfections
COS-1 and T47D cells (Cancer Research U. K. cell resources
unit) were grown in a 5% CO2 atmosphere at 37uC in high
glucose DMEM supplemented with 10% foetal bovine serum and
50 U/ml penicillin G and 50 mg/ml streptomycin (Gibco) and
2 mM L-glutamine for COS-1 and T47D cells, respectively. For
transfections the T47D cells were grown in RPMI 1640 (phenol
red-free) containing 5% dextran-charcoal stripped foetal bovine
serum. Transient transfections of COS-1 cells and T47D cells were
performed in six-well plates using DEAE-dextran according to
Cullen [35] and Lipofectamine 2000 (Invitrogen), respectively.
24 hours post transfection, medium containing 50 nM compound
F, CF, [33] for PPARd activation and/or 500 nM rosiglitazone,
BRL, [36] for PPARc1 activation in a final concentration of 0.1%
dimethyl sulfoxide (DMSO) or DMSO alone was added. 48 hours
post transfection cell lysates were generated using Promega’s
reporter lysis buffer.
For all transfections 500 ng luciferase reporter (pLFABPluc or
p46UAS-TK-luc) and 50 ng pSVb-galactosidase were used per
well in six-well plates. Luciferase activity was assayed with the
Promega luciferase assay substrate and b-galactosidase activity
according to Sambrook et al. using o-nitrophenyl-b-D-galactopyr-
anoside [27] or using the chemiluminescent b-gal reporter gene
assay kit from Roche.
Statistical analysis
Relative reporter gene expression is stated as the luciferase
activity normalized against the corresponding b-galactosidase
activity. These values have in turn been normalised against the
mean of the normalized luciferase activities of the leftmost bars in
each graph. Each experiment was repeated three times and the
bars in the graphs represent the means and the error bars
represent the standard error of the mean. One-way ANOVA was
performed on the data from each experiment and the Newman-
Keuls test was employed for calculating statistical significance
using GraphPad Prism 3 software.
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